Form 4 for SABS SAB Biotherapeutics, Inc.
Accepted 2022-05-23 00:00:00 ET · period of report 2022-05-20 · accession 0001209191-22-031398 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-23 | 2022-05-20 | SABS | Reich Samuel J | Executive COB, Dir | J - Other | $0.00 | +207.0K | 208.0K | +20,700% | $0 | |
| I | 2022-05-23 | 2022-05-20 | SABS | Reich Samuel J | Executive COB, Dir | J - Other | $0.00 | -2.50M | 547.7K | -82% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-20 | J | A | 207,001 | $0.00 | 208,001 | D | — | — | (F2) The Reporting Person received 207,001 shares as part of the distribution, which the Reporting Person previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis. |
| 2 | Common | Common Stock | 2022-05-20 | J | D | 2,500,127 | $0.00 | 547,698 | I Via Big Cypress Holdings LLC | — | — | (F1) Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a managing member of Big Cypress Holdings LLC, and as part of the distribution will receive 207,001 shares of the issuer, which the Reporting Person previously had an indirect pecuniary interest. |